For AOE due to
P aeruginosa and S aureus
AOE, acute otitis externa.
For AOE due to P aeruginosa and S aureus
Just one dose,
right in your office
See the benefit of
OTIPRIO (ciprofloxacin otic suspension) 6% is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.
Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of non-susceptible bacteria and fungi. If such infections occur, institute alternative therapy.
Acute otitis externa clinical trial: Adverse reactions (incidence at least 2%) with OTIPRIO vs sham were: ear pruritus (2% vs 2%), headache (2% vs 1%), otitis media (2% vs 1%), and ear discomfort (2% vs 0%).
Pediatric Use: The safety and effectiveness of OTIPRIO in infants below six months of age have not been established for the treatment of acute otitis externa.
OTIPRIO (ciprofloxacin otic suspension) 6% is a fluoroquinolone antibacterial indicated for the treatment of acute otitis externa in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.
Please click link below for full Prescribing Information.
OTIPRIO is being marketed by ALK-Abelló, Inc. and Otonomy, Inc.
OTIPRIO is a registered trademark of Otonomy, Inc.
©2020 Otonomy, Inc. All rights reserved. OTI0243.1220